Bristol-Myers Squibb Company Common Stock (BMY)
Stock · NYSE · Health Care
$59.83as of 10/16/2026
Price chart
Active signals
BMY Signal Track Record
How signals performed across all stocks →What BMY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +0.7% | 53% | September 23, 2026 |
| Bollinger Band Breakout | 24 | -1.0% | 46% | August 19, 2026 |
| Bollinger Band Breakdown | 22 | +0.4% | 55% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.7% | 70% | October 5, 2026 |
| Any 20-session window (baseline) | -0.5% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 32,500
- Website
- www.bms.com
Fundamentals
- 1-day range
- $59.54$61.43
- Market cap
- $131.04B
- P/E (trailing)
- 13.53
- P/E (forward)
- 9.04
- EPS (trailing)
- $4.54
- Dividend yield
- 4.58%
- Beta
- 0.19
- Avg. volume
- 11.58M
- Ex-dividend date
- October 2, 2026
- Dividend pay date
- November 2, 2026
How Bristol-Myers Squibb Company Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
24 analyst ratings
Bristol-Myers Squibb Company Common Stock Competitors
Chosen by industry and closest market cap.
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- REGNRegeneron Pharmaceuticals Inc. Common Stock$790.74▼ 0.70%Market cap $79.49BP/E 19.00$564$859.34
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 19.00 | $790.74 | ▼ 0.70% | $564$859.34 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Redwire vs. Rocket Lab: Which Industrials Stock Is a Better Buy in 2026?Yahoo · 10/10/2026
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?Yahoo · 10/10/2026
- Why Is Everyone Ignoring Gilead Stock's High Cash Yield?Yahoo · 10/10/2026
- Does The Move In Merck Stock Change Anything?Yahoo · 10/9/2026
- Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a WarningYahoo · 10/9/2026
- What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?Yahoo · 10/9/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 10/9/2026
- 2 Profitable Stocks to Target This Week and 1 We Find RiskyYahoo · 10/9/2026
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructurebenzinga · 10/7/2026
Insider Activity
Insider Actions →- Cari Gallman · October 2, 2026 · Option Exercise4.6K
- Cari Gallman · October 2, 2026 · Tax Withholding2.3K @ $61.15
- Theodore R. Samuels II · September 30, 2026 · Grant821 @ $62.4
- McMullen Michael R. · September 30, 2026 · Grant561 @ $62.4
- Derica W. Rice · September 30, 2026 · Grant621 @ $62.4
- Peter J. Arduini · September 30, 2026 · Grant561 @ $62.4
- Phyllis R. Yale · September 30, 2026 · Grant561 @ $62.4
- Cristian Massacesi · September 9, 2026 · Sale6.2K @ $64.57
- Bartie Wendy Short · September 1, 2026 · Option Exercise1.2K @ $66.92
- Bartie Wendy Short · September 1, 2026 · Tax Withholding633 @ $66.92
- Phil M. Holzer · August 25, 2026 · Sale500 @ $67.5
- Cari Gallman · August 1, 2026 · Option Exercise1.1K
- Cristian Massacesi · August 1, 2026 · Option Exercise51.2K
- Cristian Massacesi · August 1, 2026 · Tax Withholding26.2K @ $65.31
- Cari Gallman · August 1, 2026 · Tax Withholding543 @ $65.31
Institutional Ownership
March 31, 2026
- Total shares held
- 1.49B
- Total value held
- $85.53B
- Institutional holders
- 2506
- Unknown171.68M
- Unknown132.32M
- Unknown98.56M
- Unknown61.12M
- Unknown55.29M
- Unknown32.59M
- Unknown29.63M
- Unknown29.20M
- Unknown26.47M
- Unknown24.99M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus
Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.